Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Dow
Medtronic
Express Scripts
Baxter

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 10,233,154

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,233,154
Title:Crystalline forms of an NK-1 antagonist
Abstract: The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1- -yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.
Inventor(s): Bacilieri; Christian (Breganzona, CH), Frasca; Gionata (Minusio, CH)
Assignee: Helsinn Healthcare SA (Pazzallo-Lugano, CH)
Application Number:15/918,868
Patent Claims: 1. A non-solvated micronized crystalline free-base form of the compound 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1- -yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is Form I, having an X-ray powder diffraction pattern comprising at least one peak, in terms of 20 at 4.5.degree..+-.0.2.degree..

2. The crystalline form of claim 1, having an X-ray powder diffraction pattern comprising the following peaks, in terms of 2.theta.: 4.5.degree..+-.0.2.degree.; 11.5.degree..+-.0.2.degree.; and 13.1.degree..+-.0.2.degree..

3. The crystalline form of claim 1, having an X-ray powder diffraction pattern comprising the following peaks, in terms of 2.theta.: 4.5.degree..+-.0.2.degree.; 8.4.degree..+-.0.2.degree.; 11.5.degree..+-.0.2.degree.; 13.1.degree..+-.0.2.degree.; 13.9.degree..+-.0.2.degree.; 14.8.degree..+-.0.2.degree.; 16.7.degree..+-.0.2.degree.; 17.4.degree..+-.0.2.degree.; 17.7.degree..+-.0.2.degree.; 19.5.degree..+-.0.2.degree.; 21.2.degree..+-.0.2.degree.; 21.6.degree..+-.0.2.degree.; and 21.8.degree..+-.0.2.degree..

4. The crystalline form of claim 1 which is substantially isolated.

5. A pharmaceutical composition comprising a non-solvated crystalline micronized free-base form of the compound 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1- -yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is Form I, having an X-ray powder diffraction pattern comprising at least one peak, in terms of 20 at 4.5.degree..+-.0.2.degree., and one or more pharmaceutically acceptable excipients.

6. The pharmaceutical composition of claim 5, wherein the crystalline form has an X-ray powder diffraction pattern comprising the following peaks, in terms of 2.theta.: 4.5.degree..+-.0.2.degree.; 11.5.degree..+-.0.2.degree.; and 13.1.degree..+-.0.2.degree..

7. The pharmaceutical composition of claim 5, wherein the crystalline form has an X-ray powder diffraction pattern comprising the following peaks, in terms of 2.theta.: 4.5.degree..+-.0.2.degree.; 8.4.degree..+-.0.2.degree.; 11.5.degree..+-.0.2.degree.; 13.1.degree..+-.0.2.degree.; 13.9.degree..+-.0.2.degree.; 14.8.degree..+-.0.2.degree.; 16.7.degree..+-.0.2.degree.; 17.4.degree..+-.0.2.degree.; 17.7.degree..+-.0.2.degree.; 19.5.degree..+-.0.2.degree.; 21.2.degree..+-.0.2.degree.; 21.6.degree..+-.0.2.degree.; and 21.8.degree..+-.0.2.degree..

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Boehringer Ingelheim
McKesson
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.